Search research articles
Contact Us
Filters
Showing results (221-230 of 264) with videos related to
Page
of 27
Sort By:
Breast Cancer Research and Treatment
|
April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Karin Ribi, Weixiu Luo, Barbara A Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
JAMA Network Open
|
May 4, 2026
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
Carmine Valenza, Yue Zheng, Monica Milano, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
NPJ Breast Cancer
|
September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
Justin M Balko, Luca Licata, Xiao Qian Wang, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart, Marion Procter, Debora Fumagalli, et al.
The Lancet. Oncology
|
August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 264) with videos related to
Sort By:
Page
of 27
Breast Cancer Research and Treatment
|
April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Karin Ribi, Weixiu Luo, Barbara A Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
JAMA Network Open
|
May 4, 2026
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
Carmine Valenza, Yue Zheng, Monica Milano, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
NPJ Breast Cancer
|
September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
Justin M Balko, Luca Licata, Xiao Qian Wang, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart, Marion Procter, Debora Fumagalli, et al.
The Lancet. Oncology
|
August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Page
of 27